This webinar will examine the impact of Major Depressive Disorder (MDD) and Bipolar I Disorder (BP-I) on workplace productivity. It covers the diagnostic criteria and epidemiology for both disorders, highlighting the economic burden, including direct and indirect costs, and productivity loss. It also addressesbarriers to care and contemporary treatment paradigms for MDD and BP-I. Furthermore, it discusses the differences between these two disorders, the impact of misdiagnosis, and various treatment approaches, including medication, therapy, and lifestyle interventions. The presentation is comprehensive, focusing primarily on the economic and productivity implications of these mental health disorders within the workplace.

Join Kimberly Moore, PharmD, MS Medical Outcomes Science Liaison at AbbVie and:

• Understand the Diagnostic Criteria and Epidemiology of Major Depressive Disorder (MDD): Gain insights into the symptoms and prevalence of MDD and associated impacts on individuals and workplaces.
• Evaluate the Economic and Productivity Costs of MDD: Learn about the direct and indirect costs linked to MDD, including effects on workplace productivity.
• Explore the Treatment Paradigms for MDD: Discover current approaches and guidelines for treating MDD, including medication classes and therapeutic interventions.
• Understand the Epidemiology and Costs Associated with Bipolar I Disorder: Familiarize with the prevalence, diagnostic challenges, and economic implications of BP-I in workplace settings.
• Identify Barriers to Care in Patients with Bipolar I Disorder: Recognize the obstacles faced by patients in receiving appropriate diagnosis for BP-I.
• Examine Current Treatment Guidelines for Bipolar I Disorder: Learn about options to manage BP-I disorder including guideline recommendations.

You’ll leave with a better understanding of the importance of appropriate diagnosis and management for MDD and BP-I.